Cargando…
Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients
The aim of this study has been to investigate the potential of serum biomarkers used in clinical practice (CEA, CYFRA 21–1, SCC) together with the serum epidermal growth factor receptor (EGFR) and its associated ligands (EGF, TGF-α, HB-EGF) as outcome predictors of non-small cell lung cancer (NSCLC)...
Autores principales: | Romero-Ventosa, Elena Yaiza, Blanco-Prieto, Sonia, González-Piñeiro, Ana Lourdes, Rodríguez-Berrocal, Francisco Javier, Piñeiro-Corrales, Guadalupe, Páez de la Cadena, María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402684/ https://www.ncbi.nlm.nih.gov/pubmed/25918681 http://dx.doi.org/10.1186/s40064-015-0891-0 |
Ejemplares similares
-
Identification of the Cancer Cell Proliferation and Survival Functions of proHB-EGF by Using an Anti-HB-EGF Antibody
por: Sato, Shuji, et al.
Publicado: (2013) -
Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients
por: Zhou, Wenwen, et al.
Publicado: (2021) -
APF, HB-EGF, and EGF biomarkers in patients with ulcerative vs. non-ulcerative interstitial cystitis
por: Zhang, Chen-Ou, et al.
Publicado: (2005) -
Retracted: Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients
por: Healthcare Engineering, Journal of
Publicado: (2023) -
A Potent Anti-HB-EGF Monoclonal Antibody Inhibits Cancer Cell Proliferation and Multiple Angiogenic Activities of HB-EGF
por: Sato, Shuji, et al.
Publicado: (2012)